CureVac N.V. (LON: 0A9E)

Market Cap	721.24M
Revenue (ttm)	55.84M
Net Income (ttm)	-236.06M
Shares Out	n/a
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,608
Average Volume	29,310
Open	4.120
Previous Close	4.139
Day's Range	3.911 - 4.140
52-Week Range	1.780 - 4.218
Beta	n/a
RSI	55.48
Earnings Date	Apr 25, 2025

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for tre...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 1,172
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A9E

Financial Performance

In 2023, CureVac's revenue was 53.76 million, a decrease of -20.26% compared to the previous year's 67.42 million. Losses were -260.17 million, 4.47% more than in 2022.

Financial numbers in EUR